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Abstract
Background: Staphylococcus aureus is a major human pathogen and strains resistant to existing treatments
continue to emerge. Development of novel treatments is therefore important. Antimicrobial peptides represent a
source of potential novel antibiotics to combat resistant bacteria such as Methicillin-Resistant Staphylococcus aureus
(MRSA). A promising antimicrobial peptide is ranalexin, which has potent activity against Gram-positive bacteria,
and particularly S. aureus. Understanding mode of action is a key component of drug discovery and network
biology approaches enable a global, integrated view of microbial physiology, including mechanisms of antibiotic
killing. We developed a systems-wide functional association network approach to integrate proteome and
transcriptome profiles, enabling study of drug resistance and mode of action.
Results: The functional association network was constructed by Bayesian logistic regression, providing a framework
for identification of antimicrobial peptide (ranalexin) response modules from S. aureus MRSA-252 transcriptome and
proteome profiling. These signatures of ranalexin treatment revealed multiple killing mechanisms, including cell
wall activity. Cell wall effects were supported by gene disruption and osmotic fragility experiments. Furthermore,
twenty-two novel virulence factors were inferred, while the VraRS two-component system and PhoU-mediated
persister formation were implicated in MRSA tolerance to cationic antimicrobial peptides.
Conclusions: This work demonstrates a powerful integrative approach to study drug resistance and mode of
action. Our findings are informative to the development of novel therapeutic strategies against Staphylococcus
aureus and particularly MRSA.
Background
Methicillin Resistant Staphylococcus aureus (MRSA) is a
major cause of morbidity and mortality [1-4]. Indeed,
rates of MRSA infections have risen significantly in
recent years [3,5]. Strains that are resistant to existing
treatments continue to emerge and community-asso-
ciated MRSA is a major global problem [3,4,6-10].
Therefore, the development of novel prevention and
treatment strategies is a pressing concern.
Antimicrobial peptides (AMPs) are a potential source
of novel antibiotics that may be developed to combat
resistant bacteria such as MRSA [11]. AMPs are pro-
duced by virtually all living creatures as part of their
innate defences and more than 880 have been described
[12]. Ranalexin is a cationic 20 amino acid peptide, first
isolated from the American bullfrog, Rana catesbeiana,
and has a single intramolecular disulphide bond to form
a heptapeptide ring at the carboxyl terminus [13]. Rana-
lexin has potent activity against Gram-positive bacteria
in vitro, particularly Staphylococcus aureus [14]. There-
fore, ranalexin offers therapeutic potential against sta-
phylococcal infections, including MRSA.
Understanding the molecular mechanisms of antimi-
crobial action is an important facet of developing new
therapeutic strategies, particularly where drug resistance
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is a problem [15,16]. Transcriptome and proteome pro-
filing offers a powerful approach for studying antimicro-
bial inhibitory action [17-19]. In principle, the mRNA
and protein profiles generated in response to the impo-
sition of antimicrobial stress reflect modulation of parti-
cular cellular functions, and provide a signature of the
type of stress imposed. For example, expression profiling
has been applied to predict mode of action [17] and to
identify molecular targets of uncharacterised antibiotics
[18]. A network biology approach in combination with
expression profiling enables systems analysis of drug
mode of action, for example with networks of drug
interactions [20] or gene regulation [21]; for a recent
review see [22].
We took a systems-wide approach to integrate tran-
scriptome and proteome profiling of drug-exposed bac-
teria with a high-confidence functional association
network [23-25] that modelled pathway relationships for
95% of S. aureus MRSA-252 genes. MRSA-252 is an iso-
late of one of the most prevalent epidemic MRSA
clones, EMRSA-16 [26]. This approach enabled infer-
ence of twenty-two novel MRSA virulence factors and
novel complementary killing mechanisms for the antimi-
crobial peptide ranalexin, including effects at the cell
wall. We also found evidence supporting involvement of
the VraRS two-component system in cationic peptide
resistance. Furthermore, FtsH was proposed as a candi-
date drug target, and a role was inferred for PhoU-
mediated persister formation in S. aureus drug toler-
ance. These results demonstrate the power of this global
functional association network approach to study drug
resistance and mode of action.
Results and discussion
Ranalexin elicits significant changes in transcript and
protein levels
We determined a sublethal ranalexin concentration (20
μg/ml) that impaired, but did not abolish growth of
MRSA-252 (Figure 1, Methods). Transcriptome and pro-
teome profiling were applied to identify changes in the
ranalexin exposed MRSA-252 cultures compared to con-
trols (Methods). Microarrays identified 93 upregulated
and 105 downregulated genes (>two-fold expression dif-
ference, p < 0.05), while iTRAQ LC-MS/MS coupled
with ProQuant (Applied Biosystems) analysis identified
56 upregulated and 15 downregulated proteins by strin-
gent criteria (Methods, Additional file 1 Tables S1-S3).
No inconsistencies were observed between the transcrip-
tome and proteome profiles. Overlap in Gene Ontology
(GO) [27] annotation was observed for these datasets
although there were only a few cases of direct overlap at
the gene level. This is not uncommon for the integra-
tion of proteome and transcriptome data [28,29]. GO-
based functional profiling of these transcripts and
proteins identified 290 significantly enriched terms (p <
0.05, Methods, Additional file 1 Tables S4-S7), underlin-
ing the multi-faceted effects of ranalexin on MRSA.
Global gene functional association network
A functional association network [23-25] was developed
in order to give a probabilistic model of global gene
function in MRSA-252, and to provide a framework for
systems-wide analysis of the ranalexin response profiles.
The UniProt [30] MRSA-252 genes were network nodes,
while connections (edges) between genes (nodes) repre-
sented relationships in cell signalling and metabolism.
Details of network construction and evaluation are given
in Methods. Briefly, edges were generated using a Baye-
sian logistic regression approach, which integrated infor-
mation from Gene Ontology [27] coannotations,
STRING scores [31] and KEGG [32] pathways (Meth-
ods). The final network contained 2494 nodes (genes)
and 19076 edges (connections), with a false positive rate
(FPR) no greater than 3% over several independent test
datasets (mean FPR 2.6%). Interestingly, these FPR
values are similar to the estimated value of the func-
tional association prior (4.7%), which suggests that a sig-
nificant fraction of the ‘false positives’ may be genuine
functional relationships that were not annotated in the
test data. Overall, the network edges relate 94.5% of
MRSA-252 genes with high confidence.
Figure 1 Sublethal exposure to ranalexin (iTRAQ). Growth is
shown for duplicate samples of MRSA-252 cultured with 20 μgml-1
ranalexin (▲, Δ) and controls (■, □). Total CFU/ml is shown for
ranalexin treated samples (○) and controls (●). Ranalexin treatment
produces a temporary reduction of growth rate. Cells were
harvested for proteome profiling by iTRAQ (Methods) at OD600
0.58, or one hour after ranalexin addition.
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The node pair degree connectivity (Figure 2), as well
as the network degree and clustering coefficient distri-
butions (Additional File 2 Figures S1, S2), denote hier-
archical structure with embedded modularity that has
been previously observed for metabolic networks
[33,34]. Indeed, the gene functional association network
topology is closer to that of metabolic networks, rather
than protein interaction networks which are less modu-
lar [24,33,34]. This result seems intuitively reasonable
because gene (node) interactions in functional associa-
tion networks are expected to be shared amongst all the
members of a functional grouping, such as a signalling
pathway, which would contribute to modular topology.
Therefore, the S. aureus MRSA-252 gene association
network structure fits well with further analysis based
on module decomposition. The network was clustered
into 597 putative functional modules using the MCL
algorithm [35]. The transcriptome and proteome profiles
were mapped into these modules, and significance was
assessed against background distributions generated by
network re-sampling (Methods). A total of eleven
modules were found to be enriched with genes that dis-
played significantly altered expression in MRSA-252 cul-
tures exposed to ranalexin. Of the eleven modules, five
were upregulated and six downregulated; these results
are summarised in Table 1. A total of 58 nodes outside
these modules were classified as intermodular hubs
(Methods, Additional file 1 Table S8), which link to
multiple highly interconnected subnetworks and are
putatively important regulators of system behaviour [36].
Impact on virulence and inference of novel determinants
The genes significantly downregulated upon ranalexin
exposure (’RanaDown’) included all six of the MRSA-
252 ESAT-6 secretion system components (Figure 3),
which are central to Staphylococcus aureus pathogenesis
[37]. A highly significant module (p ≤ 1.9E-4, 7/12 nodes
RanaDown) included five ESAT-6 components; the sixth
MRSA-252 ESAT-6 gene (esaA, SAR0280) was not
assigned to a module but was RanaDown and shared
edges with 10/12 genes in the module. The two further
RanaDown genes in this module (SAR0287, SAR0288)
were relatively uncharacterised ‘hypothetical’ proteins
[30,32]. Analysis of SAR0288 predicted six transmem-
brane regions [38] and found a match to the ‘membrane
ABC permease’ domain PD089828 [39]; SAR0287 was
predicted to be secreted or cell wall anchored [38], and
matched to several protein families including conserved
domains of unknown function (e.g. DUF1342), plus viru-
lence-associated families (e.g. Sm_multidrug_ex,
WXG100) [32,40]. These results agree with the net-
work-inferred virulence function for SAR0287 and
SAR0288. The remaining five genes in the module were
also hypothetical, while all five matched to conserved
domains of unknown function (e.g. DUF1415) and viru-
lence-associated families (e.g. Endotoxin_N, WXG100)
[32,40]. Consistent with roles in virulence for these
remaining five genes, TMHMM2 [38] indicated two
secreted/cell wall and one transmembrane protein, while
predictions were not clear in two cases. The module
had good correspondence with predicted operon struc-
ture [41,42], implying that the seven hypothetical genes
may be co-regulated with the ESAT-6 system. The GO
term ‘pathogenesis’ (GO:0009405) was significant for
this module (p ≤ 4.92E-5, 5/12 annotated genes, Table
2). Therefore, seven novel S. aureus (MRSA-252) viru-
lence factors were inferred.
Two significant RanaDown modules (p ≤ 1.9E-3, 4/5
nodes RanaDown; p ≤ 6.2E-3, 4/9 nodes RanaDown)
were associated with high-affinity metal ion transport
[32,40], which is crucial for establishment of infection
[43,44]. The module with 4/5 RanaDown genes included
SAR0787-SAR0790, representing the sst iron-uptake
operon [45]. The fifth gene in this module (SAR1011)
was a putative substrate binding protein for iron
Figure 2 Normalised probability of network degree pairs. The
axes represent the degree of interacting nodes (genes). The z axis
scale indicates the ratio p(k1, k2)):pr(k1, k2). p(k1, k2) is the
probability of observing an interacting pair of nodes in the MRSA
network with degrees k1, k2 and pr(k1, k2) is same probability in
the randomised MRSA network [102,103]. Therefore, the bottom left
area of the plot represents connections between nodes that have
low degree values, the area at the top right represents connections
between nodes that have high degree values. Individual pair values
of p(k1, k2)):pr(k1, k2) range from to 0.01 to 34.0. Values given on x
and y axes represent bin lower bounds, a cutoff was applied at
degree of 70 due to degree pair sparseness above this value. The
observed degree pair distribution reflects hierarchical structure with
embedded modularity [34]. This figure was generated using R [95].
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complex transport [32], which agrees with the functional
relationship to the sst operon inferred from the network.
A further module (p ≤ 6.2E-3, 4/16 nodes RanaDown)
contained twelve genes with annotated virulence func-
tions. These twelve genes were largely implicated in
colonization (e.g. binding fibronectin, bone sialopro-
teins) and immuno-modulation (e.g. IgG binding,
clumping factor A) [30,32,40,46]. The remaining four
genes in this module encoded EbpS (SAR1489), a puta-
tive lyrA protease (SAR2421), a putative lytN cell wall
hydrolase (SAR1223), and a conserved hypothetical pro-
tein (SAR1802) matching to the Pfam family ‘hydrolase’
[30,32,40]. Indeed, coordination of peptidoglycan hydro-
lase and virulence determinant expression has been
observed in S. aureus [47,48]. All sixteen genes were
known or predicted to encode cell wall anchored, trans-
membrane or secreted proteins [30,38,40]. The GO term
‘pathogenesis’ (GO:0009405) was significant for the
module (p ≤ 6.64E-8, 8/16 annotated genes). These data
imply functions in virulence-coupled autolysis for
SAR2421 (lyrA), SAR1223 (lytN) and SAR1802
(hypothetical). EbpS (SAR1489) is a transmembrane pro-
tein that binds (soluble) tropoelastin, and not associated
with adhesion [49]. EbpS function is not well defined,
however involvement in virulence is suggested by the
network structure. A fully connected RanaDown module
Table 1 Ranalexin response modules
Module description Ranalexin Altered Gene Set Additional Genes In Module False discovery
rate adjusted p-
value
+ Val/Leu/Ile metabolism SAR2141, SAR2143, SAR2144,
SAR2146, SAR2147, SAR2148 (6/7*
genes)
SAR2297 <9.0E-5*
+ Na+/H+ antiporters (mnh
operons)
SAR0629-SAR0635, SAR0908 (8/17*
genes)
SAR0909-SAR0915, SAR0627, SAR0628 <9.0E-5*
+ Persister formation,
phosphate transport (pstSCAB-
phoU operon)
SAR1400-SAR1402, SAR1398 (4/4
genes)
- 1.2E-4
+ Chaperones, stress response SAR0938, SAR1657, SAR1658 (3/3
genes)
- 0.027
+ Osmoprotectant transport SAR2536-SAR2538 (3/6 genes) 3 genes: SAR2535, SAR0775, SAR0776 0.046
- Virulence factors (ESAT-6
system)
SAR0279, SAR0281-0284, SAR0287,
SAR0288 (7/12* genes)
SAR0285, SAR0286, SAR0289, SAR0290, SAR0291 <1.9E-4*
- High-affinity metal ion
transport (Fe)
SAR0787-SAR0790 (4/5 genes) SAR1011 0.0019
- Virulence factors (Colonization,
immuno-modulation)
SAR0567, SAR0847, SAR2508
SAR2709 (4/16 genes)
SA0566, SAR0842, SAR1102, SAR1103, SAR1223, SAR1489,
SAR1802, SAR1841, SAR2383, SAR2421, SAR2580,
SAR2734
0.0062
- High-affinity metal ion
transport (Fe, Zn, Mn, Mo)
SAR0274, SAR0643, SAR2594,
SAR2452 (4/9 genes)
SAR1633, SAR1928, SAR2361, SAR2543, SAR2544 0.0062
- Virulence (inferred from
network)
SAR0292-SAR0294 (3/3 genes) - 0.025
- Cell division SAR1177-SAR1179 (3/4 genes) SAR1175 0.028
A prefix ‘+’ in the first column indicates modules with upregulated genes, a prefix ‘-’ downregulated genes. *No instances of these module coverage levels were
observed in the appropriate random sampling. Therefore the background frequency was set to 1/100000 for estimation of p-values.
Figure 3 ESAT-6 downregulated module and novel virulence
factors. Genes significantly downregulated by ranalexin (RanaDown)
are shown in pink, other genes in yellow. Two significant network
modules are shown (p ≤ 0.025, p ≤ 1.9E-4). Names (e.g. esxA) are
given for genes that have been characterised, and these all
represent ESAT-6 system components; otherwise locus identifiers are
given (e.g. SAR0294). Network edges are shown as blue lines. Novel
virulence roles were inferred for the SAR0292-0294 module and the
seven uncharacterised genes in the ESAT-6 module (see main text).
These network-based predictions are supported by several further
lines of evidence, including predicted cellular localisation, domain
matching and operon structure. This figure was generated in
Cytoscape [104].
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(p ≤ 0.028, 3/3 nodes RanaDown) was composed of rela-
tively uncharacterised, ‘hypothetical’ genes (SAR0292,
SAR0293, SAR0294). Interestingly, the only edge from
this module into the rest of the network connected with
the ESAT-6 virulence module described above (Figure
3). Consistent with the network-based inference of viru-
lence functions for these three genes, TMHMM2 indi-
cated one transmembrane and two secreted/cell wall
proteins, while database matches included conserved
domains of unknown function (e.g. DUF600) and RTX
toxin family (RTX) [38,40].
Additionally, the most significantly enriched GO term
in the ranalexin downregulated gene set was ‘pathogen-
esis’ (GO:0009405, p ≤ 7.78E-9, n = 14) (Additional file 1
Table S7). Many genes annotated with this GO term
were strongly downregulated, for example: SAR2122
(hld, encoding delta-haemolysin; 0.19-fold); SAR1022
(sspA, encoding a glutamyl endopeptidase; 0.21-fold);
SAR2648 (ssaA1, encoding staphylococcal secretory anti-
gen precursor; 0.28-fold). Indeed, several agr locus genes
additional to hld were RanaDown (agrB 0.38-fold, agrC
0.48-fold, agrD 0.42-fold, rnaIII 0.15-fold). Ranalexin
dependent repression of virulence genes agrees with the
upregulation of sarA attenuator SAR1374 (msrR, 2.24-
fold), which inhibits sarA-dependent virulence gene
expression [50]. Furthermore, two RanaDown genes
(SAR0115, SAR2474) encoded putative HTH-type tran-
scriptional regulators (sarS, sarZ) from the sarA family,
that activate virulence factor transcription [51,52]. There
is evidence linking traditional antibiotics to reduction of
S. aureus virulence (reviewed in [53]), however this had
not previously been reported for a cationic AMP. The
observation that ranalexin results in repression of viru-
lence factor expression has clear beneficial implications
for potential clinical applications (e.g. catheter surfac-
tant, nasal cream).
Prediction of additional S. aureus virulence factors was
enabled by mapping GO annotations for ‘pathogenesis’
(GO:0009405) into the network (Methods). A total of
ten modules were significant (p ≤ 0.05, size >2), and
were manually inspected (Table 2). These ten included
the ESAT-6 and colonization-associated modules dis-
cussed above. Interestingly a significant module (p ≤
2.38E-5 7/19 GO:0009405) had 15 known two-compo-
nent sensors or regulators, and a further four poorly
characterised genes which may form novel virulence-
associated two-component systems. Manual inspection
of these modules, with reference to literature and elec-
tronic resources (e.g. UniProt [30], KEGG [32]), indi-
cated eight genes not previously annotated as virulence
factors (SAR0068, SAR0426, SAR0760, SAR1331,
SAR1332, SAR2167, SAR2449, SAR2450).
In summary, the above analysis indicated that rana-
lexin restricts S. aureus MRSA-252 pathogenicity,
including the ESAT-6 system, and inferred twenty-two
novel virulence factors.
Table 2 Significant virulence modules.
Module Summary Genes annotated with GO:0009405
(’pathogenesis’)
Additional Genes In Module False discovery
rate adjusted p-
value
Colonization,
immunomodulation
SAR1102 SAR0842 SAR2580 SAR0567
SAR2383 SAR2709 SAR2508 SAR2734
SAR0566 SAR0847 SAR1841 SAR1103 SAR1223
SAR2421 SAR1489 SAR1802
6.64E-8
Staphylococcal enterotoxins SAR1920 SAR1919 SAR1916 SAR1921
SAR1917 SAR1918
- 1.69E-7
Superantigen-like proteins SAR0424 SAR0427 SAR0425 SAR0422
SAR0423
SAR0426 7.10E-7
Two-component (sensor,
response regulator) systems,
drug resistance
SAR0670 SAR2448 SAR1426 SAR2447
SAR1427 SAR0758 SAR0669
SAR0068 SAR1772 SAR2167 SAR1771 SAR1567
SAR1332 SAR1331 SAR2449 SAR1568 SAR0019
SAR2450 SAR0760
2.38E-5
ESAT-6 system SAR0283SAR0282SAR0284SAR0279SAR0281 SAR0285 SAR0287SAR0288 SAR0289 SAR0290
SAR0291 SAR0286
4.92E-5
Superantigen-like proteins SAR1141 SAR1140 SAR1139 - 6.36E-5
Superantigen-like proteins SAR0431 SAR0428 SAR0429 - 6.36E-5
gamma-hemolysin SAR2511 SAR2509 SAR2510 - 6.36E-5
Response regulators (MarR,
SarR)
SAR2379 SAR0739 SAR2351 - 6.36E-5
Peptidases SAR1022 SAR1020 SAR1021 SAR2716 2.22E-4
Modules with false discovery rate corrected Fisher p-values ≤ 0.05 and size >2 are given. All modules were manually inspected with reference to literature and
relevant databases (e.g. [30,32]). Underlined locus identifiers were downregulated in response to ranalexin, none of the below loci were upregulated. Locus
identifiers in bold are candidate novel virulence factors. Many genes that were not annotated with ‘pathogenesis’ in the Gene Ontology nevertheless had some
association with virulence in the literature, and therefore are not indicated as candidate novel virulence factors in the table. Modules listed first ‘Colonization,
immunomodulation’ and fifth ‘ESAT-6 system’ were also significant for the ranalexin downregulated gene set (Table 1).
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Ranalexin induces cell wall stress
The response to ranalexin included strong upregulation
of several peptidoglycan synthesis genes, which suggests
that ranalexin may act on the cell wall (Additional file 1
Table S4). Indeed, the Gene Ontology (GO) term ‘pepti-
doglycan-based cell wall’ (GO:0009274) was significantly
enriched in genes upregulated by ranalexin (RanaUp) (p
≤ 0.03, n = 3). The VraR (SAR1974) regulator protein of
the vancomycin-resistance associated two-component
system (VraSR) was RanaUp (2.45 fold). VraSR controls
the expression of genes that are induced by vancomycin,
many of which function in cell wall biosynthesis [54,55].
Several genes regulated by VraSR were found to be
RanaUp, including SAR1461 (penicillin-binding, pbp2,
2.10-fold), SAR1964 (glycosyltransferase, mgt, 2.64-fold),
SAR1030 (methicillin resistance-related, fmt, 2.45-fold)
and SAR2442 (teicoplanin resistance, tcaA, 3.08-fold).
The above genes include members of a general cell wall
stimulon induced in response to cell wall active agents
[56-58]. Moreover, VraSR is upregulated in vancomycin-
intermediate strains of S. aureus and induced by expo-
sure to cell wall active antibiotics such as glycopeptides
and b-lactams [55,59]. A further RanaUp protein, FtsH
(encoded by SAR0512, 1.23-fold), had the highest
betweenness centrality in the network, degree of 74 (top
0.5%), and did not fall into a module. Therefore FtsH is
an intermodular hub, which implies a key role in regu-
lating system behaviour [36]. Indeed, FtsH is within the
AAA (ATPases Associated with diverse cellular Activ-
ities) family and acts as a chaperone required for incor-
poration of penicillin binding proteins (PBPs) into the
cell membrane [60,61]. As noted above, pbp2 was
RanaUp and is part of a cell wall stimulon, while PBPs
are upregulated in vancomycin-intermediate S. aureus
(VISA) [57]. FtsH is also involved in response to osmo-
tic stress and mutants are non-viable or have signifi-
cantly attenuated virulence [61,62]. Considering the
above, FtsH is proposed to be a key player in the MRSA
response to antimicrobials such as ranalexin and a
potential drug target. Indeed, these results suggest that a
drug targeting FtsH would be particularly effective in
combination with cell wall active agents. The upregula-
tion of FtsH in concert with the cell wall stimulon
further supports action of ranalexin at the cell wall. The
largest ranalexin dependent induction of transcription
was observed for SAR0584 (vraX, 23.89-fold), which is
not well characterised. However, vraX was over-
expressed in isolates of vancomycin-intermediate S. aur-
eus (VISA) and showed >200-fold increased expression
in vancomycin-sensitive S. aureus (VSSA) treated with
vancomycin [59]. Overall, these data indicate that rana-
lexin caused cell wall stress similar to that produced by
vancomycin - a cell wall active antibiotic.
RanaUp genes also included transcriptional regulatory
proteins encoded by SAR1689 (GreA, 4.00-fold) and
SAR0625 (SarA, 4.36-fold) that are known to be induced
in the presence of cell wall active antibiotics [59,63]. A
transcriptional attenuator of SarA, SAR1374 (msrR,
2.24-fold), was induced by ranalexin. Significantly, msrR
is induced upon exposure to cell wall active antibiotics,
while its deletion results in sensitivity to methicillin and
teicoplanin [50]. An autolysis-deficient, teicoplanin-resis-
tant strain of MRSA was found to upregulate fmtA,
sarA, tcaA, msrR, vraR plus a large number of proteases
[64]. As noted above, these genes were found to be
RanaUp. Indeed, inactivation of MRSA methicillin resis-
tance genes has been reported to increase susceptibility
to the b-defensin and LL37 AMPs [65]. Evidence sup-
porting upregulation of cell wall anabolism also included
enrichment of the GO term ‘aspartate family amino acid
biosynthesis’ in the RanaUp set (GO:0009067, p ≤ 1.45E-
3, n = 5). Aspartate metabolism produces essential com-
ponents for pepdidoglycan biosynthesis, such as diami-
nopimelic acid, and components of the aspartate
pathway represent possible drug targets [66].
In summary, the above results suggest that ranalexin
exposure induced a cell wall stress response, similar to
that associated with cell wall active antibiotics or glyco-
peptide intermediate-resistant S. aureus (GISA) strains.
Follow-up laboratory experiments were performed to
further investigate these findings (below).
Further investigation of ranalexin cell wall effects
The physiological relevance of ranalexin induced cell
wall related gene and protein expression changes was
investigated by producing vraR and tcaA disruption
mutants and subsequent examination for peptide sensi-
tivity. Prior to making mutants, ranalexin induced
enhanced expression was verified by quantitative PCR
for vraR (previously detected by iTRAQ) and tcaA
(detected by microarray analysis) (Figure 4). In both
cases, we again detected ranalexin dependent induction
of expression after 15 minute (min) exposure that
peaked after 30 min and subsequently declined after 60
min.
The Sigma TargeTron system was applied to generate
disruption mutants, for which the S. aureus laboratory
strain RN4220 was recommended by the manufacturer.
Thus, the corresponding genes from MRSA-252 were
identified in RN4220 and disrupted. VraR disruption
induced sensitivity to both ranalexin (Additional file 2
Figure S3) and vancomycin (data not shown), compared
to the parent strain. Complementation experiments
were attempted, but were inconclusive due to phenoty-
pic effects induced by the empty cloning vector. Growth
of the vraR mutant was identical to the parent strain in
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the absence of ranalexin, but was completely inhibited
when ranalexin was added (Additional file 2 Figure S3).
Similarly, dose response experiments revealed dramatic
viability loss for the vraR mutant both to increasing
concentrations (up to 160 μg ml-1) and to increased
duration of exposure (up to 2 h) - contrasting with the
parent strain which retained viability (Additional file 2
Figure S3). Considering that the VraRS two-component
system regulates a response to cell wall damage [67],
these results support the view that ranalexin induces
cell wall stress. TcaA disruption resulted in minor sensi-
tivity to ranalexin (Additional file 2 Figure S3). No sig-
nificant differences in rate of loss of viability between
the tcaA mutant and the parent strain exposed to rana-
lexin were detected (data not shown). TcaA is a member
of the cell wall stress stimulon known to be induced by
exposure to antibiotics in a VraRS dependent fashion
[68]. Therefore, these results suggest that VraRS may be
a staphylococcal two-component response regulator
involved in cationic peptide resistance. In S. aureus,
VraRS regulates the transcriptional induction of genes
involved in cell wall peptidoglycan biosynthesis and is
crucial for resistance to cell wall active antibiotics such
as the glycopeptides vancomycin and teicoplanin
[55,59,67]. Therefore, these results support the view that
ranalexin’s mode action includes disruption of the sta-
phylococcal cell wall.
To further examine ranalexin cell wall effects, osmotic
fragility was measured for MRSA cells exposed to sub-
lethal concentrations of antimicrobials (Figure 5).
Osmotic fragility is a hallmark of cell wall disruption
[69,70]. Cultures were incubated in TSB, in the presence
and absence of vancomycin or ranalexin, harvested and
washed twice in sterile distilled water, followed by incu-
bation in water for 105 min. Viability was determined
throughout the experiment. Control cells (RN4220) and
vraR-disrupted cells showed negligible loss of viability
or sensitivity to hypo-osmotic stress. As expected, cells
pre-treated with a sub-lethal concentration of vancomy-
cin were sensitive. Notably, pre-treatment with a sub-
lethal concentration of ranalexin also induced sensitivity
to hypo-osmotic stress (Figure 5). Furthermore, expo-
sure to both ranalexin and vancomycin induced a simi-
lar degree of osmotic fragility compared to treatment
with ranalexin; suggesting commonalities in modes of
action. Coupled with the induction of increased cell wall
related gene/protein expression and hypersensitivity pro-
duced by vraR disruption, these results imply that the
inhibitory action of ranalexin is not solely due to mem-
brane disruption [13], but also involves significant
effects at the staphylococcal cell wall.
Figure 4 Quantitative RT-PCR confirms upregulation of vraR
and tcaA by ranalexin. Fold induction of vraR and tcaA expression
measured by qRT-PCR after 15, 30 and 60 min exposure to 20 μg
ml-1 ranalexin. Gene expression was normalised against 16SrRNA
and fold-induction upon exposure to ranalexin treatment was then
determined relative to untreated controls. The experiment was
performed in triplicate and the data shown represents the mean
and standard error of the mean.
Figure 5 Ranalexin exposure induces sensitivity to hypo-
osmotic stress. Cells of S. aureus RN4220 were exposed to sub-
lethal concentrations of ranalexin (10 μg ml-1; ♦); vancomycin (0.8
μg ml-1; ▲); ranalexin + vancomycin (10 μg ml-1 + 0.8 μg ml-1; ●) in
TSB, compared with untreated cells (■) and untreated cells of the
vraR mutant in TSB (□). After 30 min incubation in TSB cells were
harvested, washed twice with distilled water to remove the
antimicrobials and resuspended in distilled water. Viable counts
were determined throughout the experiment. Error bars represent
the standard error of the mean (n = 3).
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MRSA persister formation and drug tolerance
Exposure to ranalexin was found to produce strong
upregulation of proteins encoded by the pstSCAB-phoU
operon PstS (SAR1402, 22.10-fold), PstC (SAR1401,
11.73-fold), PstA (SAR1400, 6.47-fold), PhoU (SAR1398,
5.99-fold) and PstB (SAR1399, 8.01-fold) (Additional file
1 Table S1). Four of these (SAR1398, SAR1400-
SAR1402) formed a significant network module (p ≤
1.2E-5, 4/4 nodes RanaUp, Table 1). SAR1399 did not
fall into a module but had connections to all the above
genes.
PhoU acts as a persister switch in E. coli multidrug
tolerance and impacts on widespread processes beyond
inorganic phosphate (Pi) transport [71]. Genetic disrup-
tion of the pstC transmembrane component of the Pi
transporter with the Sigma TargeTron system did not
have any effect on ranalexin sensitivity (data not
shown). Combined with the proteome profiling and net-
work analysis this data suggests that MRSA adopts a
PhoU-mediated persister phenotype to acquire antimi-
crobial tolerance, and that upregulation of the Pi trans-
porter is not a major component of this response.
Indeed, the pstSCAB-phoU operon was induced by
Streptococcus pneumoniae exposure to penicillin [72],
and targeted disruption correlated with increased sensi-
tivity to ciprofloxacin in Mycobacterium smegmatis [73].
A pyrimidine metabolism module was RanaDown (p ≤
0.028, 3/4 nodes RanaDown) reflecting growth inhibition
that is a hallmark of persister formation [74]. Addition-
ally, several other cell division proteins were RanaDown,
including SAR0017 (PurA, 0.62-fold, intermodular hub),
SAR1047 (PurH, 0.27-fold), SAR2000 (PurB, 0.7-fold),
SAR1180 (PyrF 0.82-fold), and the transcript SAR1040
(purC, 0.48-fold) was RanaDown. These genes (or oper-
ons as applicable) are therefore tentative candidates for
negative regulation by PhoU in MRSA-252. The results
presented in earlier sections, finding ranalexin exposure
upregulated cell wall anabolism and reduced virulence,
also align with persister formation. Indeed, persister bac-
teria exhibit thickening of the cell wall and loss of viru-
lence factors [75]. These findings underline the
importance of persister formation in MRSA drug
tolerance.
Multiple actions in MRSA killing
Ranalexin is canonically associated with cell membrane
permeabilisation [13]. In agreement with this, a cation
antiport module was significant upregulated (p ≤ 9.0E-5,
8/17 nodes RanaUp). The RanaUp genes in this module
were subunits A-F (SAR0630-SAR0635) of the Na+/H+
antiporter encoded by the mnh2 operon, SAR0629
(phage integrase family protein) and subunit G
(SAR0908) of the Na+/H+ antiporter encoded by the
mnh operon [76]. The module also included subunits A-
F from the mnh operon, and three hypothetical proteins
(SAR0628, SAR0627, SAR0915). The upregulation of
these ‘electrogenic monovalent cation proton antiporter-
3’ operons [77] implies that membrane permeabilisation
leading to cation influx and possible dissipation of trans-
membane electrochemical gradient is a major effect of
ranalexin exposure. The mnh and mnh2 operons are
important for Na+-dependent pH homeostasis in B. sub-
tilis and are induced by alternative sigma factor B (sB)
in S. aureus [78]. Further, the GO term ‘ion transport’
(GO:0006811, p ≤ 0.020, n = 9) was significantly
enriched with upregulated genes. Additional to the
above genes, these included SAR0723 (cadA, 2.06-fold),
encoding a probable cadmium-effluxing P-type ATPase
that confers resistance to Cd2+ toxicity [79]; SAR0110
(2.14-fold) encoding a putative Na+/Pi-cotransporter;
SAR0139 (2.09-fold), encoding a putative tetracycline, K
+ or Na+/H+ antiporter [80]; and SAR2233 (czrA, 2.49-
fold), encoding a regulatory transcription factor induced
in response to Zn2+ stress [81]. A significant module (p
≤ 0.046, 3/6 nodes RanaUp) contained the opuC osmo-
protectant transport operon (SAR2535-SAR2538); osmo-
protectant transporters are thought to be strongly
dependent on sB induction [78,82]. Upregulation of
osmoprotectant transport is likely a product of sB
induction by cation influx, especially given the observed
upregulation of the mnh and mnh2 operons. Interest-
ingly, increased osmolarity would be expected to act in
concert with the ranalexin cell wall effects presented
above in producing hypo-osmotic fragility and disrup-
tion of cell integrity. Therefore the membrane and cell
wall actions of ranalexin may exert complementary
effects in killing S. aureus MRSA-252.
The response signature included upregulation of the
dlt operon D-alanine and D-alanyl lipoteichoic acid
synthesis, which leads to increased positive charge at the
cell surface and reduced peptide binding [83]. Consis-
tent with the expected ranalexin induced stress, a signif-
icant module (p ≤ 0.027, 3/3 nodes RanaUp) contained
chaperones and stress response genes. Also, the chaper-
one proteins GroEL (encoded by SAR2116, 1.56-fold)
and FtsH (encoded by SAR0512, 1.23-fold) were RanaUp
and intermodular hubs [36]. Another significant module
(p ≤ 9.0E-5, 6/7 nodes RanaUp) represented genes for
Val/Leu/Ile synthesis (Table 1), which utilizes pyruvate
[84], and therefore may allow for greater glycolytic flux
in powering ranalexin stressed cells. Indeed, several glu-
cose catabolism and uptake proteins were upregulated,
including EIIA-Glc (encoded by SAR1435, 2.65-fold),
PGK (encoded by SAR0829, 1.13-fold) an intermodular
hub, and PGI (encoded by SAR0924, 1.22-fold) substan-
tiating upregulation of glycolysis upon ranalexin expo-
sure. Interestingly, L-LDH1 (encoded by SAR0234, 0.77-
fold) was RanaDown; in conjunction with upregulation
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of Val/Leu/Ile synthesis and glycolysis this suggests
repurposing of pyruvate into production of hydrophobic
proteins for peptide sequestration [85]. These results,
and those presented in above sections, detail several
lines of defence employed by MRSA to escape the
effects of cationic AMPs.
In summary, evidence supports multiple inhibitory
actions for ranalexin including cell wall effects, increased
cation influx and possible dissipation of transmembrane
electrochemical gradient. MRSA attempts several survi-
val strategies when faced with antimicrobial peptide
(ranalexin) stress, and evidence was found for comple-
mentary inhibitory actions in killing MRSA.
Conclusions
A global gene functional association network that cov-
ers 95% of S. aureus MRSA-252 genes was presented.
Careful benchmarking against blind test datasets found
a false positive rate no greater than 3% in the final net-
work. Functional network analysis of drug response
signatures enabled novel insights into the mode of
action of a cationic antimicrobial peptide (AMP), rana-
lexin, as well as insights into MRSA-252 antimicrobial
resistance mechanisms. Evidence was presented for
novel ranalexin effects on the bacterial cell wall, in
addition to the previously characterised action at the
cell membrane [13], and these actions were proposed
to act in concert. These findings agree with previous
observations that cationic AMPs exert complex inhibi-
tory actions [86]. The FtsH membrane chaperone was
an intermodular hub [36], upregulated in response to
ranalexin and suggested as a promising candidate drug
target, particularly for combination therapy with cell
wall active agents. Indeed, combination therapy has
clear advantages for treatment of resistant bacteria
[87,88]. Additionally, the two-component response reg-
ulator VraR was suggested to be important for mediat-
ing tolerance to antimicrobial peptides. Therefore,
VraRS may be a staphylococcal two-component
response regulator involved in cationic peptide resis-
tance, in addition to apsRS [89,90]. Ranalexin exposure
produced MRSA-252 virulence reduction, and twenty-
two novel virulence factors were inferred. These novel
roles in virulence are supported by several additional
lines of evidence, including predicted cellular localisa-
tion [38], domain matching [40] and operon structure
[41,42]. Finally, we present evidence to support PhoU-
mediated persister switching as a mechanism of drug
tolerance in MRSA; which merits further investigation
as a route towards novel therapeutic targets. This work
is informative to the development of therapeutic stra-
tegies against S. aureus, and demonstrates an elegant
approach to study drug resistance and mode of action.
Methods
Peptide
Ranalexin was synthesised according to the published
sequence [13] by Peptide Protein Research Ltd, Wick-
ham, UK, to >95% purity and verified by HPLC and
mass spectrometry. A stock solution of 50 mg ml-1 in
water was used.
Cell growth
Staphylococcus aureus MRSA-252 was a gift from Prof.
Mark Enright, Imperial College London. A glycerol
stock of S. aureus MRSA-252 stored at -80°C was
streaked and maintained on Tryptone Soya Agar (TSA;
Oxoid, Basingstoke, UK).
Starter cultures of S. aureus MRSA-252 were grown
overnight in 25 ml of Tryptic Soya Broth (TSB; Oxoid,
Basingstoke, UK) at 37°C in an orbital shaker at 220
rpm. For iTRAQ protein extraction; four flasks contain-
ing 25 ml of fresh TSB were then inoculated with these
cells to give an identical starting optical density at 600
nm (OD600) of 0.01 in each flask. The cultures were
then shaken at 220 rpm until an OD600 of 0.3 was
reached. At this point 20 μg ml-1 ranalexin was added
to two culture flasks and an equivalent volume of water
to the remaining two cultures. The cultures were then
incubated at 37°C with shaking at 220 rpm. Cultures
were harvested when they reached an OD600 of 0.55-0.6,
for the ranalexin treated cultures this corresponded to 1
hour exposure. Cell viability was measured simulta-
neously via serial dilution and plating on TSA. Growth
of S. aureus RN4220 (a gift from Prof. Simon Foster,
University of Sheffield), and gene disrupted strains made
in this background, were grown to mid-exponential
phase in 10 ml TSB and diluted to a starting OD600 of
0.001 in 100 μl TSB in a 96-well plate (Greiner). Rana-
lexin was added and the cell growth monitored and
recorded over 24 h at 37°C with constant shaking in a
PowerwaveXS (BioTek) plate reader. Data were collected
using KC4 v.3.2 software and analysed in Microsoft
Excel.
Similarly, viability of S. aureus RN4220 and gene dis-
rupted strains with or without ranalexin exposure was
measured by serial dilution and plating on TSA.
Protein expression analysis using isobaric Tags for
Relative and Absolute Quantitation (iTRAQ)
Protein extracts were prepared from duplicate, mid-
exponential cultures of S. aureus MRSA-252 grown in
TSB at 37°C (Oxoid) as above. Cells were harvested by
centrifugation at 2500 g for 15 min. The cell pellets
were washed twice in sterile distilled H2O, and proteins
extracted by bead beating (Biospec) in triethyl ammo-
nium bicarbonate (TEAB; Sigma) buffer (0.5 M, pH8.5)
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containing 0.1% w/v SDS. The cells were then pelleted
and resuspended in 1 ml fresh buffer. Crude cell
extracts were prepared from this cell suspension by
bead beating. This procedure was performed using 1.5
ml of glass beads (Biospec) with 4 bursts of 1 min each
and 1 min rest intervals on ice. Protein concentrations
were determined using the Calbiochem non-interfering
protein assay kit and with BSA as standards. Protein
was then labelled with iTRAQ reagents following the
manufacturer’s protocol (Applied Biosystems). Briefly,
20 μl (55 μg) of each sample was reduced and the
cysteine residues blocked with MMTS before digesting
each sample with trypsin. Following an overnight (16 h)
tryptic digestion each sample was labelled with one of 4
isobaric iTRAQ reagents, designated 114, 115, 116 and
117, since each carries a reporter group with approxi-
mately these molecular masses. In this experiment,
iTRAQ reagents 114 and 115 were used to label the
duplicate control samples while 116 and 117 were used
to label the duplicate ranalexin treated samples (see Fig-
ure 1). After labelling, the 4 samples were combined
into one tube and then fractionated by cation exchange
chromatography in order to simplify the samples prior
to analysis by LC-MS/MS. The combined sample was
diluted with 7 ml of 10 mM KH2PO4, 25% v/v acetoni-
trile (pH 3.0; adjusted with 1 M H3PO4) and then
loaded onto an equilibrated cation exchange column.
The column was then washed with 2 ml of 10 mM
KH2PO4, 25% v/v acetonitrile buffer. Then the labelled
peptides were eluted from the column by washing with
12 aliquots of 600 μl elution buffer (1 M KH2PO4,
K2HPO4), which contained KCl at concentrations of 40,
50, 60, 70, 80, 90, 100, 120, 140, 165, 220 and 280 mM,
respectively. These 12 eluted fractions were collected
separately and stored at -20°C prior to analysis by LC-
MS/MS.
The buffer was removed under reduced pressure and
the samples resuspended in 0.5% formic acid for mass
spectrometric analysis. Peptides were separated using an
UltiMate nanoLC (LC Packings, Amsterdam) equipped
with a PepMap C18 trap & column, using a 3.5 hr gra-
dient of increasing acetonitrile concentration, containing
0.1% formic acid (5-35% acetonitrile in 3 hr, 35-50% in
a further 30 min, followed by 95% acetonitrile to clean
the column). The eluent was sprayed into a Q-Star Pul-
sar XL tandem mass spectrometer (Applied Biosystems,
Foster City, CA) and analysed in Information Dependent
Acquisition (IDA) mode.
Protein identification and quantification
The raw iTRAQ data from Analyst 1.1 (Applied Biosys-
tems) was analysed with ProQuant (Applied Biosystems),
this gave confidence scores for peptide identifications
and quantitative data based on the 114, 115, 116 and
117 peak intensities found in the MS/MS spectra. The
output data were viewed through the ProGroup Report
viewer software (Applied Biosystems). The data in the
ProGroup report included a list of all proteins identified
(with a confidence of 99% or greater) and also the ratios
of the level of each identified protein in the control
samples (labelled 114 and 115) versus the ranalexin trea-
ted samples (labelled 116 and 117). Each ratio was cal-
culated from the ratios of the individual peptides
identified as being derived from that protein. In the
ProGroup Report all ratios were returned with calcu-
lated p-values, which indicated the likelihood that the
ratios do not differ significantly from 1. For each protein
a total of 4 expression ratios and their corresponding p-
values were considered in the analysis; 116/114 (rana-
lexin1/control1), 116/115 (ranalexin1/control2), 117/114
(ranalexin2/control1), and (117/115 ranalexin2/control2).
These p-values were combined by Fishers method and
proteins with Benjamini-Yekutieli false discovery rate
corrected p-value > 0.05 were excluded [91]. A further
filtering step excluded proteins where any of the four
ratios described above had p-value > 0.05. Protein
expression changes were expressed as the mean of the
four statistically significant expression ratios. iTRAQ
data are available from the PRIDE database (accession
numbers 14807-14816) [92].
RNA extraction for microarrays
For RNA extraction (in triplicate); 10 ml of TSB was
inoculated to an OD600 of 0.01, and, similar to the
iTRAQ experiment above, 20 μg ml-1 ranalexin was
added at an OD600 of 0.3 and cells harvested after 30
min incubation with peptide. 20 mL RNAprotect (Qia-
gen) was added to the 10 ml cultures and processed
according to manufacturer’s instructions. Pellets were
stored frozen at -80°C. Pellets were thawed at room
temperature and washed in TE buffer (1 ml 10 mM
Tris, 1 mM EDTA, pH 8.0). After removing the super-
natant, pellets were resuspended in TE containing 200
μg ml-1 lysostaphin, 400 units ml-1 mutanolysin and 40
μg ml-1 proteinase K and incubated at 37°C for 90 min
with gentle mixing. Then 4 ml RLT buffer from the
RNeasy midi kit was added to the mixture and pro-
cessed according to manufacturer’s instructions. This
was followed by on-column DNA digestion using
RNase-free DNase (Qiagen), according to manufacturer’s
instructions. RNA was eluted in 250 μl RNase-free water
and eluted again using the same 250 μl. The concentra-
tion and the quality of the RNA was measured using an
Agilent 2100 Bioanalyzer (Agilent Technologies).
Microarray hybridisation and analysis
cDNA was synthesised from the RNA extracted from
both control and ranalexin treated cultures using
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SuperScript II and random hexamers (Invitrogen) and
labelled with either Cy3 or Cy5-dCTP (GE Healthcare).
Three independent biological replicates of the control
culture and ranalexin treatment were performed and the
RNA derived from these was labelled and co-hybridised
as two dye-swapped technical replicates, providing a
total of six arrays for analysis. Hybridisation, washing
and scanning of the S. aureus microarray (SAv1.1.0) was
undertaken as described previously [93]. The array
design is available in BμG@Sbase (accession number: A-
BUGS-17; http://bugs.sgul.ac.uk/A-BUGS-17) and also
ArrayExpress (accession number: A-BUGS-17).
Feature extraction was performed using ImaGene v5.5
(BioDiscovery) and the microarray data were normalised
and statistically analysed using GeneSpring v7 software
(Agilent Technologies). Data points that were flagged by
ImaGene as present or marginal were only included in
the analysis. The data were median normalised and the
averaged normalised expression ratios of ranalexin ver-
sus control were calculated for each gene. To identify
differentially expressed genes in response to ranalexin
treatment, the data were filtered to detect genes that
had a greater than two-fold expression difference with a
t-test p-value < 0.05 when the Benjamini & Hochberg
false discovery rate correction [94] was applied. Fully
annotated microarray data has been deposited in
BμG@Sbase (accession number: E-BUGS-65; http://bugs.
sgul.ac.uk/E-BUGS-65) and also ArrayExpress (accession
number: E-BUGS-65).
MRSA-252 gene functional association network
A graph was constructed by a supervised learning
approach in order to model MRSA-252 global gene
function. Genes were nodes and edges represented func-
tional association in signalling and metabolic pathways.
The 2639 MRSA-252 genes in the Uniprot [30] database
(taken on 21/11/08) have a possible 3480841 unique
pairs; by reference to the UniProt XML we were able to
assign co-annotated Gene Ontology (GO) terms for
1358130 pairs (1742 genes). The 679 coannotated GO
terms were placed into ten bins each with similar num-
bers of pairs, and an eleventh bin contained the pairs
with no coannotated GO term. Frequency values for
each bin were assigned as a fraction of the total pairs.
The STRING database (v8.0) [31] had 81290 unique
pairwise scores for MRSA-252 (2618 genes). These pairs
were placed into ten bins, with an eleventh bin for pairs
without STRING scores, and bin frequency values calcu-
lated as described above.
Gold-standard datasets to define functionally related
and functionally unrelated sets of genes were derived
from the 102 MRSA pathways described in KEGG ver-
sion 48 [32]. Manual inspection of the 102 pathways
removed three considered to be overly broad functional
groupings. The three excluded pathways were ‘ABC
transporters’ (sar02010), ‘Aminoacyl tRNA biosynthesis’
(sar00970) and ‘Two-component system’ (sar02020),
additionally ribosomal RNAs were excluded from the
pathway ‘Ribosome’ (sar03010). The positive data, repre-
senting functionally related genes, were all remaining
pairs within each of the 99 selected MRSA-252 KEGG
pathways (9835 unique pairs, 1162 genes). The negative
data, representing functionally unrelated genes, were all
pairs formed between genes from different pathways
(198500 unique pairs, 1162 genes). Uniprot identifiers
were mapped to KEGG identifiers by reference to the
Uniprot XML [30]. Ten percent from each of the posi-
tive and negative datasets was randomly selected from
each STRING and GO bin combination (TEST-N).
TEST-N was set aside as blind test data not used in the
network development. The data remaining after subtrac-
tion of TEST-N comprised 8861 positive and 178640
negative pairs (TRAIN-N).
From TRAIN-N, the probabilities that a given pair of
genes is functionally associated were estimated from the
coannotated GO term frequency bin values (pGO)
according to Bayes rule (Equation 1).
P(Int|Freq) = P(Freq|Int)P(Int)
P(Freq)
(1)
Where:
P(Freq | Int) is the probability of obtaining the bin fre-
quency value given the genes are functionally related.
P(Int) is the prior probability that genes are function-
ally related.
P(Freq) is the prior probability of the bin frequency
value.
The same formula was applied to estimate the prob-
ability that a given pair of genes is functionally asso-
ciated from the STRING frequency values (pSTRING).
Logistic regression was applied to combine pSTRING
and pGO values into a single functional association
probability estimate. For this purpose balanced training
(TRAIN-B) and testing (TEST-B) datasets were respec-
tively developed by random selection of negative exam-
ples from TRAIN-N and TEST-N. The logistic
regression model was fitted over TRAIN-B with the R
function glm [95] and is given in Equation 2.
P =
1
1 + e−(6.369+0.947pGO+1.104pSTRING)
(2)
Where:
pGO is the Bayesian probability that the pair of genes
are functionally related from the coannotated GO term
data.
pSTRING is the Bayesian probability that the pair of
genes are functionally related from the STRING data.
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Functional association probabilities were generated for
all 3480841 unique MRSA-252 gene pairs according to
Equation 2, thereby generating the initial network. Addi-
tional file 2, Figure S4 shows a receiver-operator charac-
teristic plot for these functional association probabilities
over the TEST-N and TEST-B datasets. The F-measure
[96] of information retrieval over TRAIN-N was used as
a guide to determine a threshold (P ≥ 0.75) to generate
the high-confidence network (Additional file 2 Figure
S5). This network had 2494 nodes and 19076 edges; the
true negative rates over TEST-N, TEST-B were 0.970,
0.983 respectively. A final blind test dataset (TEST-Z,
3403 pairs) included the one completely new MRSA-252
pathway (sar03018) added to KEGG after the network
was generated, plus the amino-acyl-tRNA biosynthesis
(sar00970) and two-component system (sar02020) path-
ways which had previously been excluded from the
gold-standard (above). The thresholded network true
negative rate over TEST-Z was 0.980. The network is
available in several formats from Additional File 3
MRSA-252_network.zip.
Mapping proteomics and microarray data into the
functional association network
Of the 103 downregulated MRSA-252 genes from the
microarray experiment, 88 shared at least one edge with
another network node. Of the 93 upregulated genes, 83
shared at least one edge with another network node.
The 56 upregulated and 15 downregulated proteins
from the ProQuant (Applied BioSystems) analysis
included identifiers from a mixture of different data-
bases and different strains. These 71 identifiers were
mapped to the protein products of 71 unique MRSA-
252 genes using stringent sequence searching critera
(BLASTP [97]) alignment, 95% query coverage, 98%
identity). At least one edge with another network node
was shared by 54/56 upregulated and 15/15 downregu-
lated proteins.
Network modules, significance assessment and
intermodular hubs
The MCL algorithm [35] (inflation value (I) of 3, other-
wise default parameters) was applied to define 597 puta-
tive functional modules, formed from 2005 genes in the
high-confidence network. The clustering with I = 3 was
chosen because the distribution of module sizes was
considered to give a more meaningful representation of
MRSA metabolic and signalling pathways. This is
because the I = 3 clustering produced comparatively few
very large modules. The clustering efficiency reported
by the clm program [35] at I = 2 (default value) and I =
3 was very close (0.44, 0.46 respectively). The distribu-
tion of module sizes is shown in Additional file 2 Figure
S6. Therefore, 489 (19.6%) genes in the network were
not assigned to a module. The set of genes significantly
affected by ranalexin exposure, as defined by the micro-
array and proteomics data, were assigned to network
modules. The significance of the enrichment of rana-
lexin affected genes in network modules was estimated
empirically by resampling. The background distributions
for the microarray data were drawn from the 2012
genes that were both represented in the network and
detected on all 6 microarrays. The background distribu-
tions for the proteomics data were drawn from the 522
proteins that were both identified at 95% confidence in
the iTRAQ experiment and mapped to genes in the net-
work. A total of 100,000 draws of size N were randomly
taken from the network, where N is the size of the test
gene set. For example, N = 83 for the background distri-
bution generated for the 83 genes in the upregulated
microarray set. Four background distributions were thus
generated, (corresponding to up- and downregulated
gene sets from the microarray and proteomics experi-
ments. p-values estimated from these distributions were
false discovery rate corrected [94].
In order to estimate significance of putative modules
predicted function for Gene Ontology [27] annotations,
Fishers test was applied. The false discovery rate cor-
rected [94] hypergeometric p-value reflects the signifi-
cance of function enrichment for the given network
module.
Intermodular hubs were defined as those nodes in the
top ten percent of both degree and betweeness central-
ity, that also fell outside the modules identified by MCL.
Betweenness was calculated using NetworkAnalyzer
[98].
Gene Ontology profiling
The microarray and proteomics datasets were analysed
by Gene Ontology (GO) [27] profiling using Fisher’s
exact test. The microarray reference dataset comprised
all genes that were flagged as present or marginal by the
feature extraction software (GeneSpring, Agilent) for 6/6
microarrays. The proteomics reference dataset com-
prised all proteins identified above 95% significance by
ProQuant (Applied BioSystems) analysis of the iTRAQ
data, including those where expression ratios were not
significantly affected by ranalexin treatment. The identi-
fers for molecules in the microarray and proteomics
datasets were mapped to UniProt [30] with reference to
the UniProt XML, and the PIR [99] mapping to Uni-
Prot. The UniProt GO mapping for Staphylococcus aur-
eus was used to assign GO terms to the reference
datasets. The GO XML was parsed to ascertain the
ancestor terms from each GO term assigned. Sequence
identifiers without assigned GO terms were discarded.
Test datasets comprising those molecules from the pro-
teomics or microarray reference data that were
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identified as upregulated or downregulated were thus
defined: PU (proteomics, upregulated) PD (proteomics,
downregulated), TU (microarray, upregulated), TD
(microarray, downregulated). Background datasets for
each of the four test datasets were defined as the
remainder of the relevant reference dataset after sub-
traction of the test data. The Fisher exact test was per-
formed for every GO term associated with each of the
test datasets using R [95]. False discovery rate adjusted
[94] one-tailed p-values were calculated to assess enrich-
ment of GO terms; terms with adjusted p-values ≤ 0.05
were considered significant.
Quantitative RT-PCR
RNA was extracted in triplicate from 5 ml MRSA-252 cul-
tures at OD600 that were exposed to 20 μg ml
-1 ranalexin
for 0, 15, 30 and 60 min. Control cells were harvested at
an OD600 of 0.6. RNA extraction was carried out as
described above except the RNeasy Protect Bacteria Mnin-
kit (Qiagen) was used. RNA was eluted in 100 μl of
RNase-free water. The concentration and quality of RNA
was measured with a NanoDrop spectrophotometer
(NanoDropTechnologies, Wilmington, DE) and RNA
diluted to a working concentration of 50 ng μl-1. Gene
specific and control primers were synthesised by Sigma-
Aldrich: (vraR: Forward: AGATATCGCCGATG-
CAGTTC, vraR: Reverse: CTCTGCGCGCTTTTTCA-
TAC, tcaA: Forward: CGGACAACAAGCACAAGATG,
tcaA: Reverse: CCCAAGGCACCATTTTTCTC, 16Sr
RNA: Forward: CCAGCAGCCGCGGTAAT, 16SrRNA:
Reverse: CGCGCTTTACGCCCAATA).
qRT-PCR was performed with the iScript™ One-Step
RT-PCR Kit With SYBR® Green (Bio-Rad). Duplicate
PCR reactions, each using 100 ng of RNA from tripli-
cate RNA extractions, were carried out using a Bio-Rad
iCycler iQ under the following conditions; cDNA synth-
esis: 10 min at 50°C; iScript reverse transcriptase inacti-
vation: 5 min at 95°C; PCR cycling and detection (35
cycles): 10 sec at 95°C: 30 sec at 60°C. Melt curve analy-
sis: 1 min at 95°C, 1 min at 55°C, 10 sec at 55°C (80
cycles, increasing each by 0.5°C each cycle). Data was
analysed using Bio-RAD iQ5 software.
Ct values of test genes were normalised against 16s
rRNA expression using the model described in [100] to
calculate fold differences in transcript levels in the rana-
lexin treated samples over the untreated control. Experi-
ments were performed in triplicate.
Gene disruption
Gene disruptions were performed using the TargeTron
system (http://www.sigmaaldrich.com/sigma-aldrich/
areas-of-interest/life-science/functional-genomics-and-
rnai/targetron.html; Sigma Aldrich) and the pNL9164
vector (Sigma Aldrich), according to manufacturer’s
instructions with the following variation: PCR products
generated were ligated into pNL9164 using T4 ligase
(Promega) and transformed into E. coli dH5a (Invitro-
gen). Propagated plasmids were then transformed into S.
aureus strain RN4220 using a Micropulser (Bio-Rad).
The examined genes were highly conserved between the
two strains, while RN4220 strongly expresses the vraSR
system and tcaA in response to cell wall active agents
[54,101]. For example, to disrupt vraR, two sets of pri-
mers were selected from those designed by the proprie-
tary TargeTron website. One of these sets, where the
insertion was between bases 237 and 238 of vraR gave
positive results in a diagnostic PCR, with the gene-dis-
rupted strain giving a PCR product 900 bp larger than
that of the parental strain. Once positive disruptants
had been identified the pNL9164 plasmid was cured
according to the manufacturer’s protocol. An identical
procedure was employed to generate disrupted strains
for other genes of interest. All gene disruptions were
verified by PCR.
Additional material
Additional file 1: Supplementary tables. Table S1 summarises the
Ranalexin dependent changes in MRSA-252 protein expression, Tables S2
and S3 respectively summarise the Ranalexin dependent up and
downregulation of gene expression in MRSA-252, Tables S4-S7
summarise the significant GO terms for the above sets of up/
downregulated proteins and genes, Table S8 gives the intermodular
hubs identified from the MRSA-252 gene functional association network.
Additional file 2: Supplementary figures. Figure S1 shows the network
degree distribution, Figure S2 shows the network clustering coefficient
distribution, Figure S3 shows the increased sensitivity of gene disruption
mutants to ranalexin. Figure S4 shows Receiver Operator Characteristic
Plots for the unthresholded network, with blind test datasets TEST-N
(real-world distribution of non-interacting and interacting genes) and
TEST-B (balanced distribution). Figure S5 shows the F-measure over the
TRAIN-N dataset, which was used to determine the edge threshold for
the high-confidence network. Figure S6 shows the network module size
distribution.
Additional file 3: MRSA-252 gene functional association network. A
zip archive of the functional association network in tabdelimited, SIF and
GML formats.
Abbreviations
σB: alternative sigma factor B; AMP: Antimicrobial Peptide; FPR: False Positive
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